ヨーロッパの蛍光 in situ ハイブリダイゼーション (FISH) 市場、製品タイプ別 (消耗品、機器、ソフトウェア)、テクノロジー別 (DNA 蛍光 in situ ハイブリダイゼーション、RNA 蛍光 in situ ハイブリダイゼーション、PNA 蛍光 in situ ハイブリダイゼーション、その他)、アプリケーション別 (がん研究、遺伝子研究、感染症、個別化医療、その他)、使用法別 (臨床、研究、コンパニオン診断)、エンドユーザー別 (病院・診療所、診断研究所、製薬・バイオテクノロジー企業、契約研究機関、学術・研究機関、その他)、流通チャネル別 (小売販売、直接入札、オンライン販売、その他) - 2030 年までの業界動向と予測。
ヨーロッパの蛍光 in situ ハイブリダイゼーション (FISH) 市場の分析と洞察
がんや遺伝性疾患に関する一般の認識の高まりにより、市場の需要が高まっています。主要な市場プレーヤーは、この重要な時期にさまざまな製品の発売と承認に注力しています。さらに、FISH の改良された高度な手順の増加も、市場の需要の高まりに貢献しています。
欧州の蛍光in situハイブリダイゼーション（FISH）市場は、がんやその他の慢性疾患の増加により、2023年から2030年の予測期間に成長すると予想されています。政府やその他の団体による研究活動への多額の資金提供も、市場の成長を牽引すると予想されています。これに伴い、メーカーは市場に新製品を投入するための研究開発活動に取り組んでいます。ただし、治療手順におけるFISH技術の高コストは、市場の成長を抑制すると予想されます。特定のバイオマーカーとさまざまなプローブの需要の増加は、治療を強化するための市場成長の機会を提供すると予想されます。遺伝性疾患に対するより質の高いヘルスケアの需要の高まりと、個別化医療の採用の増加は、市場の成長を後押しすると予想されます。ただし、FISH技術に関連する倫理的な懸念と、熟練した認定専門家の不足は、市場の成長に課題をもたらすと予想されます。
Data Bridge Market Research の分析によると、ヨーロッパの蛍光 in situ ハイブリダイゼーション (FISH) 市場は、予測期間中に 7.5% の CAGR で成長し、2030 年までに 4 億 7,468 万米ドルに達する見込みです。乳がんや遺伝性疾患の患者数が増加しているため、製品タイプ セグメントが市場で最大のセグメントを占めています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021（2015～2020年にカスタマイズ可能） |
|
定量単位 |
収益は百万米ドル、価格は米ドル |
|
対象セグメント |
製品タイプ別（消耗品、機器、ソフトウェア）、技術別（DNA蛍光in situハイブリダイゼーション、RNA蛍光in situハイブリダイゼーション、PNA蛍光in situハイブリダイゼーション、その他）、用途別（がん研究、遺伝子研究、感染症、個別化医療、その他）、使用法別（臨床、研究、コンパニオン診断）、エンドユーザー別（病院・診療所、診断研究所、製薬・バイオテクノロジー企業、契約研究機関、学術・研究機関、その他）、流通チャネル別（小売販売、直接入札、オンライン販売、その他） |
|
対象国 |
ドイツ、フランス、イギリス、イタリア、ロシア、スペイン、オランダ、スイス、ノルウェー、ポーランド、スウェーデン、ベルギー、トルコ、デンマーク、フィンランド、その他ヨーロッパ諸国 |
|
対象となる市場プレーヤー |
Thermo Fisher Scientific Inc.、Bio-Techne、Abbott、Agilent Technologies、Merck KGaA、F. Hoffmann-La Roche Ltd、Abnova Corporation、BioDot、Biocare Medical、LLC、Abcam plc、Sysmex Asia Pacific Pte Ltd（Sysmex Corporationの子会社）、BIOZOL Diagnostics Vertrieb GmbH、Zytomed Systems GmbH、Genemed Biotechnologies、Inc.、Bio SB、BioGenex、Excilone、MetaSystems、Kaneka Eurogentec SA、BioCat GmbH、Leica Biosystems Nussloch GmbHなど |
市場の定義
蛍光 in situ ハイブリダイゼーション (FISH) と呼ばれる分子細胞遺伝学的手法により、細胞内の特定の DNA 配列または染色体全体の位置を特定できます。この手法は、遺伝性疾患の診断、遺伝子のマッピング、染色体異常の特定に使用され、また、関連種の異なる染色体上の遺伝子がどのように構成されているかを比較するためにも使用できます。FISH を実行すると、二重らせん構造がほどかれ、蛍光分子に接続されたすべてのプローブが、蛍光顕微鏡で確認できるサンプル DNA の特定の配列に結合されます。
FISH は、腫瘍学、予防および生殖医療、ゲノムおよび細胞生物学研究の診断目的で頻繁に使用されています。これは、感染症や染色体異常を発見するための業界で認められた方法です。ただし、FISH 製品およびプローブの承認に関する厳格な規制と基準により、市場の成長が抑制されると予想されます。
欧州の蛍光 in situ ハイブリダイゼーション (FISH) 市場の動向
このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。
ドライバー
- 遺伝性疾患とがんの負担が増大
遺伝子異常は全体としてはまれですが、個々の病気としては非常に頻繁に発生します。遺伝子の変化はすべてのがんの原因です。がんのわずか 5% から 10% が遺伝的に素因があります。それでも、家族内で同じ種類のがんが発生する場合、遺伝ががんの原因であるように見えることがあります。血液がんと固形がんはどちらも、さまざまな遺伝子異常を伴う異質な疾患です。過去 20 年間に実施されたゲノム不安定性と疾患発症の関係に関する広範な調査の結果、染色体断片の増加、喪失、または再配置や遺伝子変異などのゲノム異常が増加しており、さまざまな悪性腫瘍の発症の原動力となっています。欠失、重複、転座などのさまざまな染色体異常の臨床診断は、FISH やその他の in situ ハイブリダイゼーション技術に依存しており、これが市場の成長を牽引しています。
- FISH製品の革新と進歩
特定の DNA 配列を見つけ、遺伝性疾患を診断し、遺伝子をマッピングし、さまざまな癌を引き起こす新しい癌遺伝子または遺伝子異常を発見するための最も信頼性の高い方法は FISH です。最近の技術の進歩により、比較ゲノムハイブリダイゼーションやマルチカラー全染色体プローブを使用したマルチプレックス FISH などのアレイベースの方法を使用して、ゲノム全体を同時にスクリーニングすることが可能になりました。遺伝性疾患との戦いにおいて、FISH は細胞遺伝学の分野を根本的に変革し、現在では市場の成長を促進する信頼できる診断および研究ツールとして認められています。
拘束
- FISH検査の高コスト
FISH として知られる高分子認識技術は、DNA または DNA/RNA 二重鎖の相補性に依存しています。FISH テストは、特定の遺伝子または遺伝子セグメントを含む、人間の細胞に存在する遺伝物質を「マッピング」します。FISH テストは、病気に関連する遺伝子異常を見つけることができるため、一部の種類の癌の診断に役立ちます。コストの問題は、現代の分子診断ラボにとって最も重要な問題です。ラボが増加するテスト量とスループットを処理できるようになるだけでなく、複雑な分子アッセイの自動化により、市場の成長を抑制する試薬費用の観点からテストのコストが大幅に削減されます。
機会
- 遺伝子異常の早期発見に関する国民の意識の高まり
遺伝子検査は、遺伝性疾患の予防、治療、早期発見において患者が重要な決定を下すのに役立ちます。遺伝子検査の重要性に対する認識が低いことが、遺伝性疾患の発生率の増加につながっています。
遺伝性疾患は、通常 DNA の変異、または染色体の数や全体的な構造の変化によって引き起こされる、人に受け継がれる健康状態です。よく知られているいくつかの種類の疾患は、遺伝性遺伝子変異に関連していることが判明しています。
Henceforth, the rising awareness about the early detection of genetic disorders using the FISH technique helps in the diagnosis of genetic diseases, gene mapping, and identification of novel oncogenes or genetic aberrations contributing to various types of cancers and genetic disorders, which provides the opportunity for market growth.
Challenge
- Stringent Government Regulations for the Approval of FISH Probes
The use of FISH techniques across the globe is rapidly increasing, with the growth of the aged population and several chronic diseases, which are preventable by early diagnosis and timely treatments. At the same time, the players of the FISH technology in the market have to follow certain regulations to get approval from the upper authorities for launching the product in a region. These stringent guidelines need to be followed, and this is one of the most difficult tasks of all the steps. The pre-market approval of various medical devices varies from one country to another.
Post-COVID-19 Impact on Europe Fluorescent in Situ Hybridization (FISH) Market
The pandemic has had adverse impacts on the FISH manufacturers as well as users. The market has been significantly influenced by COVID-19, which has led to an increase in research studies utilizing FISH. One such study, published in November 2022 in the PLOS One Journal, employed a FISH-based method to detect SARS-CoV-2 in saliva. The method involved using a Cy3-labeled DNA probe specific to SARS-CoV-2, and the analysis was carried out manually using fluorescence microscopy as a proof-of-concept.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the FISH market.
Recent Developments
- In March 2023, Abcam plc. announced that it has received "Antibody Supplier of the Year" in CiteAb's distinguished annual industry awards. This comes after Fast Company recently listed Abcam plc. as one of the most innovative companies in the world for its ground-breaking efforts to increase data reproducibility. The provider with the most antibody product citations in 2022 receives CiteAb's "Antibody Supplier of the Year" honor. Moreover, Abcam plc. was given a "highly commended" rating in the category of "Post Translational Modification Antibody Supplier of the Year," recognizing the difficulty in creating and validating antibodies for these challenging targets. This has aided the business in becoming known on a Europe scale
- In March 2023, BIOZOL Diagnostics Vertrieb GmbH announced the acquisition of AlphaScience GmbH. By making this acquisition, BIOZOL Diagnostics Vertrieb GmbH strengthened its dominant position in the Europe market for research and diagnostics. With a significant number of new supplier connections, outstanding product knowledge, and staff who are well-trained technically, AlphaScience enhances BIOZOL. Significant synergy effects between the two organizations improving their offerings to customers and suppliers
- In July 2022, Bio-Techne announced the launch of the CE-IVD designated RNAscope ISH Probe High Risk HPV in Europe in order to help patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) identify high-risk Human Papillomavirus (HPV). For the qualitative identification of HPV E6/E7 mRNA in FFPE tissue samples, the RNAscope ISH Probe High Risk HPV is used. This has aided the business in offering better solutions all over the world
Europe Fluorescent in Situ Hybridization (FISH) Market Scope
The Europe Fluorescent in Situ Hybridization (FISH) market is segmented into six notable segments based on product type, technology, application, usage, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
BY PRODUCT TYPE
- CONSUMABLES
- INSTRUMENT
- SOFTWARE
Based on product type, the market is segmented into consumables, instrument, and software.
BY TECHNOLOGY
- DNA FLUORESCENT IN SITU HYBRIDIZATION
- RNA FLUORESCENT IN SITU HYBRIDIZATION
- PNA FLUORESCENT IN SITU HYBRIDIZATION
- OTHERS
Based on technology, the market is segmented into DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, PNA fluorescent in situ hybridization, and others.
BY APPLICATION
- CANCER RESEARCH
- GENETIC RESEARCH
- INFECTIOUS DISEASE
- PERSONALIZED MEDICINE
- OTHER
Based on application, the market is segmented into cancer research, genetic research, infectious disease, personalized medicine, and other.
BY USAGE
- CLINICAL
- RESEARCH
- COMPANION DIAGNOSTIC
Based on usage, the market is segmented into clinical, research, and companion diagnostic.
BY END USER
- HOSPITALS & CLINICS
- DIAGNOSTIC LABORATORIES
- PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES
- CONTRACT RESEARCH ORGANISATIONS
- ACADEMIC & RESEARCH ORGANISATIONS
- OTHERS
Based on end user, the market is segmented into hospitals & clinics, diagnostic laboratories, pharmaceuticals & biotechnology companies, contract research organizations, academic & research institutes, and others.
BY DISTRIBUTION CHANNEL
- RETAIL SALES
- DIRECT TENDER
- ONLINE SALES
- OTHERS
Based on distribution channel, the market is segmented into direct tender, retail sales, online sales, and others.
Europe Fluorescent in Situ Hybridization (FISH) Market Regional Analysis/Insights
ヨーロッパの蛍光 in situ ハイブリダイゼーション (FISH) 市場が分析され、製品タイプ、テクノロジー、アプリケーション、使用法、エンドユーザー、流通チャネルに基づいて市場規模の情報が提供されます。
この市場レポートで取り上げられている国は、ドイツ、フランス、英国、イタリア、ロシア、スペイン、オランダ、スイス、ノルウェー、ポーランド、スウェーデン、ベルギー、トルコ、デンマーク、フィンランド、およびその他のヨーロッパ諸国です。
ドイツは、FISH治療消耗品およびキットの大量生産、新興市場からの需要増加、静脈疾患治療産業の拡大により、ヨーロッパ地域を支配すると予想されています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、ヨーロッパ ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響も考慮されます。
競争環境と欧州の蛍光 in situ ハイブリダイゼーション (FISH) 市場シェア分析
ヨーロッパの蛍光 in situ ハイブリダイゼーション (FISH) 市場の競争状況は、競合他社の詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、および技術ライフライン曲線が含まれます。上記のデータ ポイントは、会社の市場への重点にのみ関連しています。
ヨーロッパの蛍光 in situ ハイブリダイゼーション (FISH) 市場で活動している主要な市場プレーヤーには、Thermo Fisher Scientific Inc.、Bio-Techne、Abbott、Agilent Technologies, Inc.、Merck KGaA、F. Hoffmann-La Roche Ltd、Abnova Corporation、BioDot、Biocare Medical, LLC、Abcam plc.、Sysmex Asia Pacific Pte Ltd (Sysmex Corporation の子会社)、BIOZOL Diagnostics Vertrieb GmbH、Zytomed Systems GmbH、Genemed Biotechnologies, Inc.、Bio SB、BioGenex、Excilone、MetaSystems、Kaneka Eurogentec SA、BioCat GmbH、Leica Biosystems Nussloch GmbH などがあります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRY INSIGHTS
4.4 CONCLUSION
5 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER
6.1.2 INNOVATION AND ADVANCEMENTS IN FISH PRODUCTS
6.1.3 HIGH FUNDING FOR RESEARCH ACTIVITIES
6.1.4 RISING DEMAND AND USAGE OF FISH TECHNIQUES
6.2 RESTRAINTS
6.2.1 HIGH COST OF FISH TESTING
6.2.2 LIMITED AVAILABILITY OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 RISING PUBLIC AWARENESS ABOUT THE EARLY DETECTION OF GENETIC ABNORMALITIES
6.3.2 RISE IN DEVELOPMENT OF SPECIFIC BIOMARKERS AND VARIOUS PROBES
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT REGULATIONS FOR THE APPROVAL OF FISH PROBES
6.4.2 ETHICAL CONCERNS ASSOCIATED WITH FISH TECHNOLOGY
7 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 CONSUMABLES
7.2.1 FISH PROBE
7.2.1.1 FISH PROBE, BY PROBE TYPE
7.2.1.1.1 CHROMOSOME FISH PROBE
7.2.1.1.2 SPLIT FISH PROBES
7.2.1.1.3 TRANSLOCATION FISH PROBES
7.2.1.1.4 SUBTELOMERE FISH PROBES
7.2.1.1.5 PRENATAL FISH PROBES
7.2.1.1.6 OTHERS PROBES
7.2.1.2 FISH PROBE, BY TECHNOLOGY
7.2.1.2.1 FLOW FLUORESCENT IN SITU HYBRIDIZATION
7.2.1.2.2 C-ISH
7.2.1.2.3 D-ISH
7.2.1.2.4 Q- FLUORESCENT IN SITU HYBRIDIZATION
7.2.1.2.5 OTHERS
7.2.1.3 FISH PROBE, BY TYPE
7.2.1.3.1 RNA
7.2.1.3.1.1 MRNA
7.2.1.3.1.2 MIRNA
7.2.1.3.1.3 OTHERS
7.2.1.3.2 DNA
7.2.2 ACCESSORY KITS & REAGENTS
7.2.2.1 KITS
7.2.2.2 BUFFER
7.2.2.3 DYES
7.2.2.4 OTHERS
7.3 INSTRUMENT
7.3.1 STANDALONE
7.3.2 PORTABLE
7.3.3 HANDHELD
7.4 SOFTWARE
8 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 RNA FLUORESCENT IN SITU HYBRIDIZATION
8.3 DNA FLUORESCENT IN SITU HYBRIDIZATION
8.4 PNA FLUORESCENT IN SITU HYBRIDIZATION
8.5 OTHERS
9 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 CANCER RESEARCH
9.2.1 CANCER RESEARCH, BY CANCER TYPE
9.2.1.1 NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS)
9.2.1.1.1 BREAST CANCER
9.2.1.1.2 LUNG CANCER
9.2.1.1.3 MELANOMA
9.2.1.1.4 PROSTRATE CANCER
9.2.1.1.5 OVARIAN CANCER
9.2.1.1.6 OTHERS
9.2.1.2 HEMATOPOETIC MALIGNANCIES
9.2.1.2.1 LEUKEMIA
9.2.1.2.2 MULTIPLE MYELOMA
9.2.1.2.3 MYELODYSPLASTIC SYNDROMES (MDS)
9.2.2 CANCER RESEARCH, BY PRODUCT
9.2.2.1 CONSUMABLES
9.2.2.2 INSTRUMENTS
9.2.2.3 SOFTWARE
9.3 GENETIC RESEARCH
9.3.1 CYTOGENETICS
9.3.2 CHROMOSOMAL ABNORMALITIES
9.3.3 OTHERS
9.4 INFECTIOUS DISEASE
9.4.1 CONSUMABLES
9.4.2 INSTRUMENTS
9.4.3 SOFTWARE
9.5 PERSONALIZED MEDICINE
9.6 OTHERS
10 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE
10.1 OVERVIEW
10.2 RESEARCH
10.2.1 INSTRUMENTS
10.2.2 CONSUMABLES
10.2.3 SOFTWARE
10.3 CLINICAL
10.3.1 CONSUMABLES
10.3.2 INSTRUMENT
10.3.3 SOFTWARE
10.4 COMPANION DIAGNOSTIC
10.4.1 CONSUMABLES
10.4.2 INSTRUMENT
10.4.3 SOFTWARE
11 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER
11.1 OVERVIEW
11.2 DIAGNOSTIC LABORATORIES
11.3 HOSPITALS & CLINICS
11.4 PHARMACEUTICALS & BIOTECHNOLOGICAL COMPANIES
11.5 ACADEMIC & RESEARCH INSTITUTES
11.6 CONTRACT RESEARCH ORGANIZATIONS
11.7 OTHERS
12 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL SALES
12.3 ONLINE SALES
12.4 DIRECT TENDER
12.5 OTHERS
13 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 U.K.
13.1.3 ITALY
13.1.4 FRANCE
13.1.5 SPAIN
13.1.6 RUSSIA
13.1.7 SWITZERLAND
13.1.8 TURKEY
13.1.9 BELGIUM
13.1.10 NETHERLANDS
13.1.11 DENMARK
13.1.12 SWEDEN
13.1.13 POLAND
13.1.14 NORWAY
13.1.15 FINLAND
13.1.16 REST OF EUROPE
14 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 MERCK KGAA
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 ABBOTT
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 AGILENT TECHNOLOGIES, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 F. HOFFMANN-LA ROCHE LTD.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 THERMO FISCHER SCIENTIFIC INC.
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ABCAM PLC.
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 COMPANY SHARE ANALYSIS
16.6.4 PRODUCT PORTFOLIO
16.6.5 RECENT DEVELOPMENTS
16.7 ABNOVA CORPORATION
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 BIO SB
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 BIOCARE MEDICAL, LLC
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 BIOCAT GMBH
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 BIODOT
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 BIOGENEX
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 BIO-TECHNE
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 COMPANY SHARE ANALYSIS
16.13.4 PRODUCT PORTFOLIO
16.13.5 RECENT DEVELOPMENT
16.14 BIOZOL DIAGNOSTICS VERTRIEB GMBH
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 EXCILONE
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 GENEMED BIOTECHNOLOGIES, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 KANEKA EUROGENTEC S.A.
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 LEICA BIOSYSTEMS NUSSLOCH GMBH
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 METASYSTEMS
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 SYSMEX ASIA PACIFIC PTE LTD (A SUBSIDIARY OF SYSMEX CORPORATION)
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
16.21 ZYTOMED SYSTEMS GMBH
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表のリスト
TABLE 1 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 EUROPE CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 5 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 6 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 7 EUROPE RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 EUROPE ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 EUROPE INSTRUMENT IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 EUROPE SOFTWARE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 13 EUROPE RNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE DNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE PNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 20 EUROPE NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 21 EUROPE HEMATOPOETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 22 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 23 EUROPE GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 EUROPE GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 25 EUROPE INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 EUROPE INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE PERSONALIZED MEDICINE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 EUROPE OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 30 EUROPE RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 EUROPE RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 32 EUROPE CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 EUROPE CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 34 EUROPE COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 36 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 37 EUROPE DIAGNOSTIC LABORATORIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE HOSPITALS & CLINICS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE PHARMACEUTICAL & BIOTECHNOLOGICAL COMPANIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE ACADEMIC & RESEARCH INSTITUTES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 44 EUROPE RETAIL SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 EUROPE ONLINE SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE DIRECT TENDER IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 EUROPE OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 49 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 50 EUROPE CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 52 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 53 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 54 EUROPE RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 EUROPE ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 EUROPE INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 58 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 59 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 60 EUROPE NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 61 EUROPE HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 62 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 63 EUROPE GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 64 EUROPE INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 65 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 66 EUROPE RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 67 EUROPE CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 68 EUROPE COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 69 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 70 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 71 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 GERMANY CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 GERMANY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 74 GERMANY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 75 GERMANY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 76 GERMANY RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 GERMANY ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 78 GERMANY INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 80 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 81 GERMANY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 82 GERMANY NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 83 GERMANY HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 84 GERMANY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 GERMANY GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 86 GERMANY INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 87 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 88 GERMANY RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 89 GERMANY CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 90 GERMANY COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 91 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 92 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 93 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 94 U.K. CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 U.K. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 96 U.K. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 97 U.K. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 98 U.K. RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 U.K. ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 100 U.K. INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 101 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 102 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 103 U.K. CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 104 U.K. NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 105 U.K. HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 106 U.K. CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 107 U.K. GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 U.K. INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 110 U.K. RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 111 U.K. CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 112 U.K. COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 113 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 114 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 115 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 116 ITALY CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 117 ITALY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 118 ITALY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 119 ITALY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 120 ITALY RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 ITALY ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 ITALY INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 123 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 124 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 125 ITALY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 126 ITALY NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 127 ITALY HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 128 ITALY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 129 ITALY GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 130 ITALY INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 131 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 132 ITALY RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 133 ITALY CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 134 ITALY COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 135 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 136 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 137 FRANCE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 138 FRANCE CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 FRANCE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 140 FRANCE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 141 FRANCE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 142 FRANCE RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 143 FRANCE ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 144 FRANCE INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 145 FRANCE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 146 FRANCE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 147 FRANCE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 148 FRANCE NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 149 FRANCE HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 150 FRANCE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 151 FRANCE GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 152 FRANCE INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 153 FRANCE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 154 FRANCE RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 155 FRANCE CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 156 FRANCE COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 157 FRANCE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 158 FRANCE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 159 SPAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 160 SPAIN CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 161 SPAIN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 162 SPAIN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 163 SPAIN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 164 SPAIN RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 165 SPAIN ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 166 SPAIN INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 167 SPAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 168 SPAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 169 SPAIN CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 170 SPAIN NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 171 SPAIN HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 172 SPAIN CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 173 SPAIN GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 174 SPAIN INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 175 SPAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 176 SPAIN RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 177 SPAIN CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 178 SPAIN COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 179 SPAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 180 SPAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 181 RUSSIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 182 RUSSIA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 183 RUSSIA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 184 RUSSIA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 185 RUSSIA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 186 RUSSIA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 187 RUSSIA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 188 RUSSIA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 189 RUSSIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 190 RUSSIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 191 RUSSIA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 192 RUSSIA NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 193 RUSSIA HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 194 RUSSIA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 195 RUSSIA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 196 RUSSIA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 197 RUSSIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 198 RUSSIA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 199 RUSSIA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 200 RUSSIA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 201 RUSSIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 202 RUSSIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 203 SWITZERLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 204 SWITZERLAND CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 205 SWITZERLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 206 SWITZERLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 207 SWITZERLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 SWITZERLAND RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 209 SWITZERLAND ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 210 SWITZERLAND INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 211 SWITZERLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 212 SWITZERLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 213 SWITZERLAND CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 214 SWITZERLAND NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 215 SWITZERLAND HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 216 SWITZERLAND CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 217 SWITZERLAND GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 218 SWITZERLAND INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 219 SWITZERLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 220 SWITZERLAND RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 221 SWITZERLAND CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 222 SWITZERLAND COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 223 SWITZERLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 224 SWITZERLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 225 TURKEY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 226 TURKEY CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 227 TURKEY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 228 TURKEY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 229 TURKEY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 230 TURKEY RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 231 TURKEY ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 232 TURKEY INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 233 TURKEY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 234 TURKEY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 235 TURKEY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 236 TURKEY NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 237 TURKEY HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 238 TURKEY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 TURKEY GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 240 TURKEY INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 241 TURKEY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 242 TURKEY RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 243 TURKEY CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 244 TURKEY COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 245 TURKEY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 246 TURKEY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 247 BELGIUM FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 248 BELGIUM CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 249 BELGIUM FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 250 BELGIUM FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 251 BELGIUM FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 252 BELGIUM RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 253 BELGIUM ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 254 BELGIUM INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 255 BELGIUM FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 256 BELGIUM FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 257 BELGIUM CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 258 BELGIUM NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 259 BELGIUM HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 260 BELGIUM CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 261 BELGIUM GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 262 BELGIUM INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 263 BELGIUM FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 264 BELGIUM RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 265 BELGIUM CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 266 BELGIUM COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 267 BELGIUM FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 268 BELGIUM FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 269 NETHERLANDS FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 270 NETHERLANDS CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 271 NETHERLANDS FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 272 NETHERLANDS FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 273 NETHERLANDS FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 274 NETHERLANDS RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 275 NETHERLANDS ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 276 NETHERLANDS INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 277 NETHERLANDS FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 278 NETHERLANDS FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 279 NETHERLANDS CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 280 NETHERLANDS NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 281 NETHERLANDS HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 282 NETHERLANDS CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 283 NETHERLANDS GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 284 NETHERLANDS INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 285 NETHERLANDS FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 286 NETHERLANDS RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 287 NETHERLANDS CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 288 NETHERLANDS COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 289 NETHERLANDS FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 290 NETHERLANDS FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 291 DENMARK FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 292 DENMARK CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 293 DENMARK FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 294 DENMARK FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 295 DENMARK FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 296 DENMARK RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 297 DENMARK ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 298 DENMARK INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 299 DENMARK FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 300 DENMARK FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 301 DENMARK CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 302 DENMARK NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 303 DENMARK HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 304 DENMARK CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 305 DENMARK GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 306 DENMARK INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 307 DENMARK FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 308 DENMARK RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 309 DENMARK CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 310 DENMARK COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 311 DENMARK FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 312 DENMARK FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 313 SWEDEN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 314 SWEDEN CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 315 SWEDEN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 316 SWEDEN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 317 SWEDEN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 318 SWEDEN RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 319 SWEDEN ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 320 SWEDEN INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 321 SWEDEN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 322 SWEDEN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 323 SWEDEN CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 324 SWEDEN NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 325 SWEDEN HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 326 SWEDEN CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 327 SWEDEN GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 328 SWEDEN INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 329 SWEDEN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 330 SWEDEN RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 331 SWEDEN CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 332 SWEDEN COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 333 SWEDEN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 334 SWEDEN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 335 POLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 336 POLAND CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 337 POLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 338 POLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 339 POLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 340 POLAND RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 341 POLAND ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 342 POLAND INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 343 POLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 344 POLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 345 POLAND CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 346 POLAND NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 347 POLAND HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 348 POLAND CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 349 POLAND GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 350 POLAND INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 351 POLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 352 POLAND RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 353 POLAND CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 354 POLAND COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 355 POLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 356 POLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 357 NORWAY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 358 NORWAY CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 359 NORWAY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 360 NORWAY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 361 NORWAY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 362 NORWAY RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 363 NORWAY ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 364 NORWAY INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 365 NORWAY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 366 NORWAY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 367 NORWAY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 368 NORWAY NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 369 NORWAY HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 370 NORWAY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 371 NORWAY GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 372 NORWAY INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 373 NORWAY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 374 NORWAY RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 375 NORWAY CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 376 NORWAY COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 377 NORWAY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 378 NORWAY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 379 FINLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 380 FINLAND CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 381 FINLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 382 FINLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 383 FINLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 384 FINLAND RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 385 FINLAND ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 386 FINLAND INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 387 FINLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 388 FINLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 389 FINLAND CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 390 FINLAND NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 391 FINLAND HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 392 FINLAND CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 393 FINLAND GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 394 FINLAND INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 395 FINLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 396 FINLAND RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 397 FINLAND CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 398 FINLAND COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 399 FINLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 400 FINLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 401 REST OF EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION
FIGURE 2 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION
FIGURE 11 THE GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER AND HIGH FUNDING FOR RESEARCH ACTIVITIES IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET FROM 2023 TO 2030
FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET
FIGURE 14 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2022
FIGURE 19 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 20 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 21 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 22 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2022
FIGURE 23 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 24 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2022
FIGURE 27 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, CAGR (2023-2030)
FIGURE 29 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, LIFELINE CURVE
FIGURE 30 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2022
FIGURE 31 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SNAPSHOT (2022)
FIGURE 39 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022)
FIGURE 40 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: PRODUCT TYPE (2023-2030)
FIGURE 43 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
